Home › Modalities › Cell

Cell (35 companies)

Ticker Company Therapeutic areas Programs Lead stage Mkt cap Programs
ACET Adicet Bio ImmunologyNeurology+2 Rare 8 Phase 1 $26.0M 8
ALLO Allogene Therapeutics ImmunologyOncology Rare 10 Phase 2 $256M 10
ANIX Anixa Biosciences Oncology 1 Phase 1 $92.8M 3
ARTV Artiva Biotherapeutics Oncology 6 Phase 1 $191M 6
AUTL Autolus Therapeutics HematologyImmunology+3 Rare 12 Approved $290M 12
BEAM Beam Therapeutics HematologyMetabolic+1 Rare 1 Phase 2 $2.14B 6
BCTX BriaCell Therapeutics Oncology 7 Phase 3 $30.7M 8
CABA Cabaletta Bio DermatologyImmunology+2 Rare 8 Phase 2 $220M 8
CAPR Capricor Therapeutics Infectious DiseaseNeurology Rare 1 NDA Submitted $489M 2
RNAC Cartesian Therapeutics ImmunologyNeurology+1 Rare 4 Phase 3 $187M 4
IPSC Century Therapeutics ImmunologyMetabolic+1 Rare 9 Phase 1 $249M 9
COYA Coya Therapeutics Neurology Rare 2 Phase 2 $70.8M 6
FATE Fate Therapeutics ImmunologyOncology+1 Rare 10 Phase 2 $124M 10
FBIO Fortress Biotech DermatologyHematology+4 Rare 2 Approved $61.4M 16
HRMY Harmony Biosciences MetabolicNeurology Rare 3 Approved $1.94B 17
IMTX Immatics Oncology 2 Phase 3 $958M 8
IMMX Immix Biopharma Hematology Rare 1 Phase 1 $603M 1
IBRX ImmunityBio Infectious DiseaseOncology 6 Approved $6.66B 17
INAB IN8bio ImmunologyOncology 3 Phase 1 $8.9M 4
INMB Inmune Bio Dermatology Rare 1 Phase 3 $29.7M 1
KAPA Kairos Pharma Oncology 1 Phase 2 $1.9M 12
KYTX Kyverna Therapeutics ImmunologyNeurology+1 Rare 6 NDA Submitted $297M 6
LEGN Legend Biotech Oncology Rare 17 Approved $3.12B 17
LCTX Lineage Cell Therapeutics MetabolicNeurology+1 Rare 13 Phase 2 $207M 13
LGVN Longeveron CardiovascularNeurology Rare 3 Phase 2 $7.1M 3
MRKR Marker Therapeutics Oncology 5 Phase 1 $14.0M 5
MESO Mesoblast CardiovascularGI/Hepatology+2 Rare 5 Approved $1.54B 5
INKT MiNK Therapeutics ImmunologyOncology+1 Rare 8 Phase 2 $47.7M 8
NKTX Nkarta ImmunologyNeurology+1 Rare 8 Phase 1 $89.6M 8
OCGN Ocugen Infectious DiseaseOphthalmology Rare 1 Phase 3 $257M 12
DTIL Precision Biosciences Infectious DiseaseMetabolic+1 Rare 1 Phase 1 $197M 5
PRME Prime Medicine GI/HepatologyRespiratory Rare 1 Phase 1 $699M 3
TARA Protara Therapeutics DermatologyMetabolic+1 Rare 2 Phase 3 $143M 3
SANA Sana Biotechnology MetabolicOncology 2 Phase 1 $563M 4
TGTX Tg Therapeutics Neurology Rare 1 Approved $9.48B 6